WisdomTree BioRevolution Fund (WDNA) Dividend Yield, History & Forecast

WisdomTree BioRevolution Fund (WDNA) is an exchange-traded fund (ETF) listed on the Chicago Board Options Exchange. It pays a current dividend yield of 3.46% ($0.77 per share annually (TTM)). The most recent ex-dividend date was December 26, 2025, with payment scheduled for December 30, 2025. market capitalization is approximately $3M. Review WDNA dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

WDNA fund composition

WDNA holds 99 positions, with 35.1% of assets in its ten largest. It charges an expense ratio of 0.45%, and manages $4.5M.

Top 10 holdings

HoldingWeight
MRNAModerna Inc7.96%
TWSTTwist Bioscience Corp6.74%
LLYEli Lilly & Co3.51%
JNJJohnson & Johnson2.86%
TXG10X Genomics Inc-Class A2.59%
IMNMImmunome Inc2.59%
NTRANatera Inc2.49%
TEMTempus Ai Inc2.17%
DARDarling Ingredients Inc2.14%
AZNASTRAZENECA PLC2.07%

Sector allocation

Healthcare90.0%Basic Materials6.1%Cash & Others4.5%Consumer Defensive3.9%Energy1.1%

Frequently Asked Questions about WisdomTree BioRevolution Fund (WDNA)

What is WisdomTree BioRevolution Fund's dividend yield?
WisdomTree BioRevolution Fund (WDNA) pays a current trailing twelve-month dividend yield of 3.46%, which works out to $0.77 per share annually based on the most recent payout schedule.
When does WisdomTree BioRevolution Fund pay distributions?
The most recent ex-dividend date was December 26, 2025. The next scheduled dividend payment date is December 30, 2025.
How many years has WisdomTree BioRevolution Fund increased its dividend?
WisdomTree BioRevolution Fund (WDNA) has increased its dividend for 1 consecutive year.
What does WisdomTree BioRevolution Fund invest in?
This fund primarily aims to meet its investment goals by employing a representative sampling method. This means it selects a portion of the securities from its benchmark index, ensuring that this smaller selection closely reflects the broader index's risk profile, expected returns, and other key characteristics. The benchmark index itself is crafted to invest in global, exchange-listed companies that are poised for significant transformation through breakthroughs in genetic research and biotechnology. It's important to note that this fund is categorized as non-diversified.